-
Mashup Score: 0
Indian drugmaker Aurobindo Pharma reported a lower third-quarter profit on Thursday, as a spike in expenses more than offset strong demand for its generic drugs.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 8White House preparing order to cut thousands of federal health workers, WSJ reports - 11 hour(s) ago
The White House is working on an executive order to fire thousands of U.S. Department of Health and Human Services workers, the Wall Street Journal reported on Thursday, citing people familiar with the matter.
Source: www.reuters.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 1
Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million Swiss francs ($235.46 million).
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
Indian drugmaker Aurobindo Pharma reported a lower third-quarter profit on Thursday, as a spike in expenses more than offset strong demand for its generic drugs.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1AstraZeneca CEO says company has no access to executive Wang, in detention in China - 15 hour(s) ago
AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker’s former senior executive Leon Wang and has provided information as needed, its chief executive said on Thursday.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million Swiss francs ($235.46 million).
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Nomura is on the cusp of its promised re-invention - 17 hour(s) ago
Kentaro Okuda promised to reinvent Nomura when he took the top job at the Japanese bank almost five years ago. It’s starting to look like he has kept his word. His next job is to convince investors that the overhaul is sustainable – and that the $20 billion firm won’t walk into another scandal.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2AstraZeneca CEO says company has no access to executive Wang, in detention in China - 19 hour(s) ago
AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker’s former senior executive Leon Wang and has provided information as needed, its chief executive said on Thursday.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2
Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million Swiss francs ($235.46 million).
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2Drugmaker AstraZeneca flags possible $4.5 million Chinese tax fine - 21 hour(s) ago
AstraZeneca could face a fine of up to $4.5 million in China over suspected unpaid taxes related to the import of two of its cancer drugs, the pharmaceuticals giant said on Thursday as it continues to gauge the impact of ongoing investigations in the key growth market.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet
Indian drugmaker Aurobindo Pharma reported a lower third-quarter profit on Thursday, as a spike in expenses more than offset strong demand for its generic drugs. https://t.co/4sv0Quz8QT https://t.co/4sv0Quz8QT